Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-tirzepatide-30mg
Tirzepatide (30mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Ready for a larger supply that supports longer-term or higher-dose protocols? The 30mg vial gives you excellent value and convenience, delivering the same powerful dual GLP-1/GIP action in a more economical format.
Tirzepatide is a synthetic 39-amino-acid peptide engineered to simultaneously activate GLP-1 and GIP receptors. This dual incretin mechanism mimics natural gut hormones, resulting in glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, and strong central appetite regulation.
Phase 3 trials (SURPASS and SURMOUNT) consistently report 15–22% average body weight reduction at higher doses, together with HbA1c decreases of 2.0–2.5% in type 2 diabetes patients. Significant reductions in visceral and liver fat are also commonly observed.
Intended Research Use
- Substantial and sustained body weight reduction
- Powerful HbA1c and fasting glucose improvements
- Appetite suppression and enhanced satiety
- Improved lipid profile and cardiometabolic markers
- Reduced visceral and liver fat content
menu_bookScientific Publications
N Engl J Med (2022)
Tirzepatide once weekly for the treatment of obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35658024/
N Engl J Med (2021)
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34170647/
Lancet (2021)
Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3)
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34370921/
JAMA (2022)
Effect of subcutaneous tirzepatide vs placebo on glycemic control (SURPASS-5)
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/35133415/
Value Option: The 30mg vial provides excellent value for extended protocols or maintenance dosing. Reconstituted at ~10 mg/mL, it allows precise measurement with smaller injection volumes.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Tirzepatide with complementary peptides can enhance weight management and metabolic outcomes.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Adds amylin-like satiety enhancement for even greater appetite control.
Tesamorelin (10mg vial)
arrow_forwardmyo-tesamorelin-10mg
Targets visceral fat reduction via GH stimulation.
AOD-9604 (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Direct lipolytic action complements tirzepatide's incretin-driven fat metabolism.
MOTS-c (10mg vial)
arrow_forwardmyo-mots-c-10mg
Mitochondrial optimization supports energy levels during caloric deficit.
Semaglutide 5mg (5mg vial)
arrow_forwardmyo-semaglutide-5mg
Comparable GLP-1 agonist for appetite suppression — studied alongside Tirzepatide for weight loss protocol comparison and sequential research designs.
Retatrutide 10mg (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Triple GLP-1/GIP/glucagon agonist with reported fat reduction up to 24% — investigated as an advanced alternative to Tirzepatide's dual mechanism.
CagriSema (Semaglutide + Cagrilintide) (5mg + 5mg vial)
arrow_forwardmyo-semaglutide-plus-cagrilintide-5mg-5mg
GLP-1 plus amylin dual-action blend offering complementary satiety mechanisms alongside Tirzepatide's incretin pathway for enhanced weight management research.
Cycling Note: Once-weekly subcutaneous injection for 12–26+ weeks.
